Nicox News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.01.25	Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 (GlobeNewswire)
21.01.25	Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights (GlobeNewswire)
04.12.24	Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream (GlobeNewswire)
02.12.24	Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected (GlobeNewswire)
19.11.24	Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial (GlobeNewswire)
17.10.24	Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results (GlobeNewswire)
14.10.24	Nicox and Soleus Sign $16.5 million Royalty and Equity Financing (GlobeNewswire)
23.09.24	Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement (GlobeNewswire)
18.09.24	Nicox Announces Approval of ZERVIATE in China (GlobeNewswire)
04.09.24	Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board (GlobeNewswire)
25.07.24	Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 (GlobeNewswire)
19.07.24	Nicox announces attendance at upcoming conferences (GlobeNewswire)
18.07.24	Nicox Provides Second Quarter 2024 Update (GlobeNewswire)
16.07.24	Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director (GlobeNewswire)
27.06.24	Nicox: 2024 Ordinary Shareholder Meeting (GlobeNewswire)
03.06.24	Number of voting rights as of May 31, 2024 (GlobeNewswire)
24.05.24	Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024 (GlobeNewswire)
06.05.24	Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 (GlobeNewswire)
02.05.24	Number of voting rights as of April 30, 2024 (GlobeNewswire)
24.04.24	Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent (GlobeNewswire)
22.04.24	Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results (GlobeNewswire)
09.04.24	Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting (GlobeNewswire)
02.04.24	Number of voting rights as of March 31, 2024 (GlobeNewswire)
22.03.24	Nicox's Shareholder Letter (GlobeNewswire)
20.03.24	Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology (GlobeNewswire)
13.03.24	Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024 (GlobeNewswire)
05.03.24	Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting (GlobeNewswire)
01.03.24	Number of voting rights as of February 29, 2024 (GlobeNewswire)
28.02.24	Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial (GlobeNewswire)
28.02.24	Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO (GlobeNewswire)
08.02.24	Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan (GlobeNewswire)
06.02.24	Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 (GlobeNewswire)
01.02.24	Number of votings rights as of January 31 2024 (GlobeNewswire)
31.01.24	Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA® (GlobeNewswire)
25.01.24	Nicox Provides Fourth Quarter 2023 Financial and Business Highlights (GlobeNewswire)
08.01.24	Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023 (GlobeNewswire)
03.01.24	Nicox : Termination of the liquidity contract with Kepler Cheuvreux (GlobeNewswire)
02.01.24	Number of voting rights as of December 31, 2023 (GlobeNewswire)
18.12.23	Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma (GlobeNewswire)
14.12.23	Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan (GlobeNewswire)
01.12.23	Number of voting rights as of November 30, 2023 (GlobeNewswire)
02.11.23	Number of voting rights as of October 31, 2023 (GlobeNewswire)
20.10.23	Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones (GlobeNewswire)
02.10.23	MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (GlobeNewswire)
01.09.23	Monthly Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights as of August 31, 2023 (GlobeNewswire)
01.08.23	Monthly Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights (GlobeNewswire)
19.07.23	Nicox Provides Second Quarter 2023 Financial and Business Highlights (GlobeNewswire)
11.07.23	Nicox: Half-year liquidity contract statement with Kepler Cheuvreux (GlobeNewswire)
10.07.23	Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million (GlobeNewswire)
03.07.23	MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	96.64	3.03 %	K V
Sonova Hldg	321.00	0.72 %	K V
CieFinRichemont	177.90	0.42 %	K V
Logitech Intl	90.60	0.38 %	K V
Swiss Re	140.45	0.25 %	K V
Holcim	91.66	-0.30 %	K V
ABB	49.91	-0.46 %	K V
Alcon	83.64	-0.50 %	K V
Geberit	509.80	-0.55 %	K V
Lonza Grp	585.00	-0.98 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nicox SA provient regroupement

Aktien Top/Flop

Meistgelesene Nachrichten